Innovative Cardisio Screening Test for Coronary Heart Disease Launches in Europe and Southern Africa

Cardisiography is the first non-invasive, highly accurate test for early detection of coronary heart disease
FRANKFURT, Germany - June 20, 2019 - PRLog -- Cardisio GmbH today announced general availability of its innovative non-invasive, highly accurate heart screening test in Europe and Southern Africa.

This European medtech startup has developed a unique medically vetted screening procedure called Cardisiography that delivers very precise results within just a few minutes. It is a non-invasive, independent, repeatable, fast, and cost-effective method of detecting arteriosclerosis in the heart. It offers a complementary and more effective alternative to traditional procedures such as stress ECG and echocardiography for early identification of heart disease.

People with coronary heart disease are usually symptom-free until the onset of a heart attack. Because the Cardisiography test is so reliable and easy to use, it has the potential to catch many heart disease cases early, and assures patients receive treatment before a potentially fatal heart attacks occurs.

"We see great potential in Cardisiography for early detection of symptom-free people with coronary heart disease. Broad-scale early detection has not been possible until now," said Dr. Sotirios Spiliopoulos, MD, Ph.D., and professor in the Clinical Department of Cardiac Surgery at the University of Graz in Austria.

Dr. Spiliopoulos has been involved in a clinical study that demonstrated Cardisiography yielding significantly better results than ever before from other non-invasive methods of CVD detection. The study has been submitted for publication in a peer-reviewed academic journal.

Cardisio's product consists of two integrated components: the Cardisiograph, a device for recording the electrical currents of the heart via five electrodes attached to the thorax, and the CardisioCloud, a software application that uses various algorithms and machine learning methods to evaluate the measurements and transmit the results within a few minutes. The Cardisio Cloud app runs on a laptop, connected to the Cardisiograph with a USB cable.

Cardisio GmbH has begun selling the test system to general practitioners, cardiologists and hospitals in several European countries via a growing network of resellers and distributors. The company has also partnered with a group of local entrepreneurs to establish a joint venture, Cardisio Southern Africa, for sales and service in a variety of southern African countries.

"Cardisio embodies a new generation of medical diagnostic systems that are mobile and Internet-based, taking advantage of the new capabilities of artificial intelligence," said Meik Baumeister, co-founder and CEO of Cardisio GmbH. "The combination of sound cardiology knowledge with intelligent high-performance algorithms offers us unprecedented opportunities. The initial response by practitioners has been overwhelming, and we are pleased that after four years of development, we can now help many people avoid a heart attack."

About Cardisio

Headquartered in Frankfurt, Germany, with offices in Berlin and San Francisco, Cardisio GmbH is a privately-held mobile health tech company that has developed a new non-invasive, highly accurate screening test for coronary heart disease. The procedure, called Cardisiography, is unique in its method and accuracy. For further information, visit or e-mail

Cardisio is a registered trademark of Cardisio GmbH.

Burghardt Tenderich
Email:*** Email Verified
Tags:Heart Screening
Location:Frankfurt - Hesse - Germany
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share